Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617927 | 0.81 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL13075650 | 0.71 | KMT2A (0.38) | MEN1KMT2ALMNACA12CA1 | |
| SCHEMBL20196454 | 0.71 | MAPT (0.37) | MAPTCA1CA2CA4CA7 | |
| SCHEMBL19357475 | 0.68 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL563377 | 0.68 | MAPT (0.43) | MEN1KMT2AMAPTLMNACA12 | |
| SCHEMBL16578355 | 0.67 | MEN1 (0.37) | MEN1KMT2AMAPT | |
| SCHEMBL13075837 | 0.66 | SIGMAR1 (0.59) | SIGMAR1 | |
| SCHEMBL9182487 | 0.65 | KMT2A (0.49) | MEN1KMT2AMAPTLMNACA12 | |
| SCHEMBL11623232 | 0.64 | APEX1 (0.46) | MEN1KMT2AMAPTLMNACA12 | |
| SCHEMBL2617907 | 0.63 | MEN1 (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399033-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2015-12-24 | — | — | US | disclosed |
| US-9096517-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-8785661-B2 | Oligome-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | MEN1 1449/4885KMT2A 3743/4885MAPT 19/4885 |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | MEN1 1449/4885KMT2A 3743/4885MAPT 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.